Study compares 2 treatments in psoriasis

Bimekizumab could be effective in treating moderate to severe plaque psoriasis.

In the Phase 3b BE RADIANT clinical trial, researchers randomly assigned nearly 750 patients with moderate to severe plaque psoriasis to receive either bimekizumab or secukinumab. After one year, the patients who were receiving secukinumab were switched to bimekizumab as part of an open-label extension of the trial.

The researchers found that the patients who received bimekizumab experienced greater improvements in their patient-reported symptoms — including itching, skin pain and scaling — clinical outcomes and health-related quality of life scores compared with those who were initially assigned to receive secukinumab. Further, the patients in the bimekizumab group achieved better psoriasis severity scores. After switching to bimekizumab from secukinumab, the patients reported greater improvement in outcomes.

The findings indicated that bimekizumab may offer patient-reported and clinical benefits in patients with moderate to severe plaque psoriasis.

Read more: JAMA Dermatology

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.